"Dr. Galsky on Maintenance Pembrolizumab in Urothelial Cancer"
Matthew Galsky, MD, director of genitourinary medical oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discusses the HCRN GU14-182 study, which looked at maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. “The current standard of treatment for patients with metastatic urothelial cancer is platinum-based chemotherapy, generally given for six to eight cycles then discontinued due to concerns of increasing toxicity with diminishing benefit,” said lead author Dr. Galsky. He added, “Initial chemotherapy could potentially induce immunogenic cell death or cause depletion of immunosuppressive cellular subsets, thereby enhancing the effects of subsequent immune checkpoint blockade.”
— Matthew Galsky, MD, Director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai